Bevacizumab boosts VA in uveitic CME

Article

A single intravitreal injection of bevacizumab can aid short-term improvement in visual acuity (VA) and decrease optimal coherence tomography (OCT) retinal thickness in patients with uveitic cystoid macular oedema (CME), according to a recent study published in the March issue of Opthalmology.

A single intravitreal injection of bevacizumab can aid short-term improvement in visual acuity (VA) and decrease optimal coherence tomography (OCT) retinal thickness in patients with uveitic cystoid macular oedema (CME), according to a recent study published in the March issue of Opthalmology.

Miguel Cordero Coma, MD and colleagues from the Massachusetts Eye Research and Surgery Institute, USA and the Department of Ophthalmology at the Hospital de León, Spain, conducted a retrospective, non-comparative, interventional case study to evaluate the short-term safety and efficacy of intravitreal bevacizumab on 13 patients undergoing treatment for CME.

The study found that six (46.2%) patients had a decrease in foveal thickness at the end of the follow-up, whereas five (38.4%) patients had an improvement of VA by ≥2 lines 84 days or more after the injection. Over the follow-up period, mean retinal thickness showed a significant decrease (p<0.02), while the change in mean logarithm of the minimum angle of resolution VA was not significant (p>0.05). Survival analysis indicated that the probability of any improvement in VA progressively increased from six weeks and reached 81% at 14 weeks.

The authors concluded that a single intravitreal injection of bevacizumab is well tolerated and can help achieve short-term improvement in VA and decreased OCT retinal thickness in patients with uveitic CME resistant to conventional therapy. It was suggested that further evaluation of intravitreal bevacizumab for uveitic CME in controlled randomized studies is necessary.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.